In recent years, global health has faced immense challenges. The COVID-19 pandemic was a reminder of the risks posed by infectious diseases and the gaps in vaccine readiness for emerging pathogens. But COVID-19 is just one piece of a much larger puzzle. Worldwide, other pathogens pose persistent, life-threatening risks, often going unnoticed despite their deadly impacts. In response to these ongoing challenges, the World Health Organization (WHO) has spotlighted 17 pathogens that urgently require vaccine development. This pivotal initiative aims to drive global attention and resources toward safeguarding public health against these high-burden, often overlooked diseases.

Each year, diseases like malaria, HIV, and tuberculosis claim 2.5 million lives. Their toll is especially heavy on low-income regions where healthcare resources are scarce. These diseases not only cause a staggering loss of life but also place immense pressure on healthcare systems, making the need for effective vaccines all the more pressing. While the world has made strides in addressing some infectious diseases, others, particularly those that are highly resistant to existing treatments continue to emerge as significant threats.

WHO’s focus on these 17 pathogens is based on rigorous analysis, informed by the disease burden and resistance trends globally. Some pathogens are familiar names; others are less recognized but no less dangerous. These pathogens have been categorized by the WHO based on the progress needed to bring their vaccines to the public. This structured approach offers a roadmap to advance the most critical vaccine candidates and targets resources to save lives efficiently.

The WHO’s list divides these 17 pathogens into three categories, each with specific implications for research and development.

1. Pathogens with No Existing Vaccines: For some pathogens, no vaccine exists, making it imperative to accelerate research to close these gaps. This category includes:

- Group A Streptococcus: Known for causing infections ranging from mild throat infections to severe invasive diseases, Group A Streptococcus has developed increasing resistance to antibiotics. A vaccine could prevent countless cases and reduce antibiotic dependency.

- Hepatitis C Virus (HCV): Affecting millions worldwide, HCV often leads to chronic liver disease, cirrhosis, and liver cancer. While treatment options have improved, a preventive vaccine remains a crucial tool to control the spread.

- HIV-1: The global struggle against HIV/AIDS continues, with millions of lives still impacted. An HIV vaccine would mark a pathbreaking advancement in public health.

- Klebsiella pneumoniae: This bacterium, responsible for severe infections such as pneumonia, bloodstream infections, and meningitis, has shown rising resistance to multiple antibiotics. A vaccine would be invaluable, especially in hospital settings where infections are difficult to control.

2. Pathogens with Existing Vaccines That Need Further Development: Some pathogens already have vaccines, but they are not fully effective, or their scope is limited. Enhancing or developing new versions of these vaccines could bring significant improvements in disease prevention:

- Cytomegalovirus (CMV): A common virus with severe consequences for immunocompromised individuals, including new-borns, CMV requires a more effective vaccine to prevent its most damaging effects.

- Broad-Spectrum Influenza: Seasonal flu vaccines require yearly updates due to flu virus mutations. A universal influenza vaccine would offer broad protection and reduce the annual burden of flu.

- Leishmania species: Leishmaniasis, primarily affecting tropical regions, causes skin sores and serious organ damage. Vaccine improvement efforts are needed to protect communities in endemic areas.

- Non-Typhoidal Salmonella: While typhoid vaccines exist, non-typhoidal strains of Salmonella cause widespread foodborne illness. Enhanced vaccines could prevent these strains and reduce global foodborne disease burden.

- Norovirus: Responsible for outbreaks of gastroenteritis, norovirus spreads rapidly, especially in close-contact environments like cruise ships and care facilities. Improved vaccines could prevent these disruptive outbreaks.

- Plasmodium falciparum (Malaria): Malaria remains a leading cause of death in many low-income regions, despite existing malaria vaccines. Improved vaccines are essential for better control and eradication efforts.

- Shigella species: A major cause of diarrheal diseases worldwide, especially in children, Shigella needs an effective vaccine to reduce its impact on vulnerable populations.

- Staphylococcus aureus: Including drug-resistant strains like MRSA, Staphylococcus aureus infections are a major concern in healthcare settings. A vaccine could reduce the incidence of these often-lethal infections.

3. Pathogens with Vaccines Nearing Approval: Some vaccines are close to completion, offering hope for expanded protection in the near future:

- Dengue Virus: Affecting millions in tropical regions, dengue fever causes severe flu-like illness and potentially fatal complications. A vaccine nearing approval could significantly reduce dengue cases.

- Group B Streptococcus (GBS): A common cause of severe infections in new-borns, GBS urgently needs an effective maternal vaccine to prevent transmission during birth.

- Extra-intestinal Pathogenic E. Coli: A frequent cause of urinary tract infections and bloodstream infections, a targeted vaccine could reduce the disease burden, particularly in hospital settings.

- Mycobacterium tuberculosis: Tuberculosis is among the most persistent infectious diseases. Improved vaccines are critical to reducing TB’s spread, especially with rising drug resistance.

- Respiratory Syncytial Virus (RSV): This virus poses serious risks to infants and the elderly, causing respiratory infections and complications. A promising RSV vaccine nearing approval could offer vital protection for these groups.

In the quest to protect public health, vaccines are among the most effective tools available. Vaccination programs have eradicated or dramatically reduced many infectious diseases, from smallpox to polio. However, the rapid rise of antimicrobial resistance (AMR) is complicating efforts to control infections that were previously treatable. When pathogens become resistant to drugs, vaccines offer a powerful alternative to prevent infection altogether.

For many of these 17 pathogens, the burden of disease is not evenly distributed. Low- and middle-income countries bear a disproportionate share of infections. This imbalance is due in part to socioeconomic factors, limited healthcare infrastructure, and environmental conditions that facilitate the spread of infectious diseases. By prioritizing vaccine development for these pathogens, WHO is targeting interventions that could save millions of lives, reduce healthcare costs, and promote equity in global health.

The WHO’s focus on these pathogens also reflects its commitment to health equity. Often, vaccine development is guided by financial considerations, investment returns, rather than the burden of disease, can drive decisions in pharmaceutical research. WHO’s initiative aims to shift this focus toward meeting the needs of underserved, high-burden communities. As Dr. Kate O’Brien, WHO’s Director of Immunisation, Vaccines, and Biologicals, noted, the study utilizes regional data to highlight the specific needs of different parts of the world.

This data-driven approach ensures that resources are directed where they are needed most, maximizing the potential impact of new vaccines. By collaborating with experts worldwide, WHO has created a comprehensive strategy that not only addresses current health threats but also builds resilience against future outbreaks.

The creation of this list is just the beginning. For meaningful change, it is essential to integrate research findings with funding initiatives and supportive policy frameworks. The WHO’s report is intended to serve as a foundation for these efforts, guiding governments, research institutions, and funding bodies to prioritize investment in these 17 pathogens. With the support of international and regional experts, this initiative provides a clear path forward for academic research, policy decisions, and global health partnerships.

WHO’s comprehensive strategy aligns with global calls for innovation in public health, including recommendations from the World Health Organization and the Lancet Commission, which have urged the development of new tools to prevent and manage infectious diseases.

Vaccines hold the potential to transform health outcomes, particularly in regions where disease burdens are high, and treatment options are limited. WHO’s prioritization of these 17 pathogens highlights the importance of proactive healthcare measures and preventive strategies. As the global community continues to face evolving health challenges, targeted vaccine development represents a vital investment in a healthier future.

Looking ahead, these efforts will require collaboration, innovation, and a sustained commitment to equity. The WHO’s initiative is a rallying call for the international community to invest in health solutions that save lives and uplift communities. In the race against infectious diseases, vaccines are not just tools, they are lifelines. By focusing on these 17 high-priority pathogens, WHO is leading the way for a world that is better prepared, more resilient, and healthier for all.